Therefore, blocking the CXCL8-CXCR1/2 axis by using small molecules or antibodies were testes, such as SB225002 (CXCL8 inhibitor binding to CXCR2) [320] to inhibit tumor progression in HER2+ breast cancer [321], and danirixin (GSK1325756) to suppress cancer migration, invasion, and metastasis. This evidence concerns the gene CXCL8 and breast carcinoma.